Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD, Kaichi Nishiwaki, MD PhD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 791.

https://doi.org/10.1182/blood.V128.22.791.791

Published: 2016

Journal Articles

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Chikashi Yoshida, MD PhD, Noriyoshi Iriyama, MDPhD, Yuho Najima, Shin Fujisawa, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD, PhD, Shinichiro Okamoto, MD PhD, Kimihiro Kawakami, MDPhD, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Kazuma Ohyashiki, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, MD PhD, Tadahiko Igarashi, MD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 1916.

https://doi.org/10.1182/blood.V128.22.1916.1916

Published: 2016

Journal Articles

the Safety and Efficacy of Deferasirox for the Transplant Patients with Iron Overload

Takayoshi Tachibana, MD, Junya Kanda, Shinichiro Machida, MD, Takeshi Saitou, Masatsugu Tanaka, MD, Yuho Najima, Satoshi Koyama, MD, Takuya Miyazaki, MD PhD, Eri Yamamoto, Masahiro Takeuchi, MD PhD, Satoshi Morita, PhD Prof, Yoshinobu Kanda, MD PhD, Heiwa Kanamori, MD, Shinichiro Okamoto, MD PhD

Blood (2016) 128 (22): 2254.

https://doi.org/10.1182/blood.V128.22.2254.2254

Published: 2016

Journal Articles

ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study

Tomoki Naoe, MD PhD, Toru Sakura, MD PhD, Yukio Kobayashi, MD PhD, Kensuke Usuki, MDPhD, Toshihiro Miyamoto, MD PhD, Hiroatsu Iida, MD PhD, Satoshi Morita, PhD, Erkut Bahceci, MD, Masahito Kaneko, RPh, Shunsuke Yamada, M.Eng, Shigeru Takeshita, MSc, Shuichi Miyawaki, MDPhD

Blood (2015) 126 (23): 1320.

https://doi.org/10.1182/blood.V126.23.1320.1320

Published: 2015

Journal Articles

Management of Adverse Events Associated with Dasatinib during Early Periods of Therapy in the Treatment of Chronic Myeloid Leukemia -a Clinical Report of Daria-01 Study

Shuichi Mizuta, MD, Hisashi Tsurumi, Masashi Sawa, MD PhD, Kana Matsumoto, PhD, Kotaro Miyao, MD, Takeshi Hara, MD PhD, Takeshi Takahashi, MD PhD, Reona Sakemura, MD, Akio Kohno, MD PhD, Mari Oba, Satoshi Morita, PhD, Junichi Sakamoto, MDPhD, Nobuhiko Emi, MDPhD

Blood (2014) 124 (21): 4537.

https://doi.org/10.1182/blood.V124.21.4537.4537

Published: 2014

Journal Articles

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

Noriyoshi Iriyama, Shin Fujisawa, MD, Maki Hagihara, MDPhD, Chikashi Yoshida, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Shinichiro Okamoto, MD PhD, Kawakami Kimihiro, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD, Junichi Sakamoto, MDPhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 3142.

https://doi.org/10.1182/blood.V124.21.3142.3142

Published: 2014

Journal Articles

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Maki Hagihara, MDPhD, Noriyoshi Iriyama, MDPhD, Chikashi Yoshida, MD PhD, Shin Fujisawa, MD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Naoki Takezako, MD PhD, Kimihiro Kawakami, MD PhD, Shinichiro Okamoto, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Takashi Kumagai, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Junichi Sakamoto, MDPhD, Satoshi Morita, PhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 1795.

https://doi.org/10.1182/blood.V124.21.1795.1795

Published: 2014

Journal Articles

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

Blood (2013) 122 (21): 3998.

https://doi.org/10.1182/blood.V122.21.3998.3998

Published: 2013

Journal Articles

A Decision Analysis of Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia In First Remission Who Lack An HLA-Matched Sibling

Blood (2010) 116 (21): 3527.

https://doi.org/10.1182/blood.V116.21.3527.3527

Published: 2010

NARROW

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

the Safety and Efficacy of Deferasirox for the Transplant Patients with Iron Overload

ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study

Management of Adverse Events Associated with Dasatinib during Early Periods of Therapy in the Treatment of Chronic Myeloid Leukemia -a Clinical Report of Daria-01 Study

The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial

A Decision Analysis of Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia In First Remission Who Lack An HLA-Matched Sibling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only